Previous studies have reported that glycogen synthase kinase inhibitors can promote GSK3β phosphorylation, induce cell senescence, and result in tumor suppression in hepatocellular carcinoma [39]. This evidence concerns the gene GSK3B and hepatocellular carcinoma.